Erkek beyaz Yeni Zelanda Tavşanında oral antidiyabetik ajanlar metformin, rosiglitazon ve repaglinid'in diyabetik anjiyopati üzerindeki etkilerinin araştırılması

Creative Commons License

Thesis Type: Postgraduate

Institution Of The Thesis: Sivas Cumhuriyet University, Sağlık Bilimleri Enstitüsü, Sağlık Bilimleri Enstitüsü, Turkey

Approval Date: 2018

Thesis Language: Turkish

Student: MERVE TAŞ

Consultant: Ahmet Altun


Background: Diabetic angiopathy is a vascular complication of diabetes mellitus. Since there are too many different therapeutic options in the treatment of diabetes mellitus, it is essential to find out differences in vasculoprotection between these drugs. Aim: we aimed to compare effects of three commonly used oral antidiabetics namely metformin, rosiglitazone, and repaglinide in diabetic angiopathy by using diabetic angiopathy model in alloxan-induced rabbits. Study Design: Male New Zealand rabbits were divided into four groups eight rabbits in each. Diabetes was induced by intravenous alloxan injection. Animals have treated either saline or antidiabetic agents including Metformin, rosiglitazone, and repaglinide for three months. Methods: Endothelial function and contractile responses of the aortic rings were evaluated by using organ bath and vascular cGMP content was assessed via radioimmunoassay method. Results: We found that both metformin, rosiglitazone, and repaglinide reversed the impairment of relaxation function caused by diabetes. Among these drugs, metformin was found to be the best in reversing the impairment of relaxation function. We demonstrated that these antidiabetic agents had increased relaxation responses of aortic rings to both endothelium-independent vasodilator agents, such as SNP, and endothelium-dependent vasodilator agent acetylcholine (Ach). Also, we managed to show these antidiabetic agents repair relaxation function via cGMP pathway. Conclusion: This study suggests that metformin might be more useful in preventing endothelial dysfunction associated complications compared to other oral antidiabetics such as rosiglitazone and repaglinide. However, the findings need to be confirmed by clinical studies that use these drugs in a significant number of patients.